NAT1 Human Gene Knockout Kit (CRISPR)
$1,657.00
4 Weeks*
Specifications
| Product Data | |
| Format | 2 gRNA vectors, 1 GFP-puro donor, 1 scramble control |
|---|---|
| Vector | GFP-puro |
| Target Symbol | NAT1 |
| Locus ID | 9 |
| Components |
KN221042G1, NAT1 gRNA vector 1 in pCas-Guide CRISPR vector, Target Sequence: GAATTGGCTATAAGAAGTCT KN221042G2, NAT1 gRNA vector 2 in pCas-Guide CRISPR vector, Target Sequence: GTCTAGGAACAAATTGGACT KN221042D, donor DNA containing left and right homologous arms and GFP-puro functional cassette. Homologous arm and GFP-puro sequences: pUC vector backbone in gray; Left arm sequence in blue; GFP-puro in green; Right arm in violet AAGGCGAGTT ACATGATCCC CCATGTTGTG CAAAAAAGCG GTTAGCTCCT TCGGTCCTCC GATCGTTGTC AGAAGTAAGT TGGCCGCAGT GTTATCACTC ATGGTTATGG CAGCACTGCA TAATTCTCTT ACTGTCATGC CATCCGTAAG ATGCTTTTCT GTGACTGGTG AGTACTCAAC CAAGTCATTC TGAGAATAGT GTATGCGGCG ACCGAGTTGC TCTTGCCCGG CGTCAATACG GGATAATACC GCGCCACATA GCAGAACTTT AAAAGTGCTC ATCATTGGAA AACGTTCTTC GGGGCGAAAA CTCTCAAGGA TCTTACCGCT GTTGAGATCC AGTTCGATGT AACCCACTCG TGCACCCAAC TGATCTTCAG CATCTTTTAC TTTCACCAGC GTTTCTGGGT GAGCAAAAAC AGGAAGGCAA AATGCCGCAA AAAAGGGAAT AAGGGCGACA CGGAAATGTT GAATACTCAT ACTCTTCCTT TTTCAATATT ATTGAAGCAT TTATCAGGGT TATTGTCTCA TGAGCGGATA CATATTTGAA TGTATTTAGA AAAATAAACA AATAGGGGTT CCGCGCACAT TTCCCCGAAA AGTGCCACCT GACGTCTAAG AAACCATTAT TATCATGACA TTAACCTATA AAAATAGGCG TATCACGAGG CCCTTTCGTC TCGCGCGTTT CGGTGATGAC GGTGAAAACC TCTGACACAT GCAGCTCCCG GAGACGGTCA CAGCTTGTCT GTAAGCGGAT GCCGGGAGCA GACAAGCCCG TCAGGGCGCG TCAGCGGGTG TTGGCGGGTG TCGGGGCTGG CTTAACTATG CGGCATCAGA GCAGATTGTA CTGAGAGTGC ACCATAAAAT TGTAAACGTT AATATTTTGT TAAAATTCGC GTTAAATTTT TGTTAAATCA GCTCATTTTT TAACCAATAG GCCGAAATCG GCAAAATCCC TTATAAATCA AAAGAATAGC CCGAGATAGG GTTGAGTGTT GTTCCAGTTT GGAACAAGAG TCCACTATTA AAGAACGTGG ACTCCAACGT CAAAGGGCGA AAAACCGTCT ATCAGGGCGA TGGCCCACTA CGTGAACCAT CACCCAAATC AAGTTTTTTG GGGTCGAGGT GCCGTAAAGC ACTAAATCGG AACCCTAAAG GGAGCCCCCG ATTTAGAGCT TGACGGGGAA AGCCGGCGAA CGTGGCGAGA AAGGAAGGGA AGAAAGCGAA AGGAGCGGGC GCTAGGGCGC TGGCAAGTGT AGCGGTCACG CTGCGCGTAA CCACCACACC CGCCGCGCTT AATGCGCCGC TACAGGGCGC GTACTATGGT TGCTTTGACG TATGCGGTGT GAAATACCGC ACAGATGCGT AAGGAGAAAA TACCGCATCA GGCGCCATTC GCCATTCAGG CTGCGCAACT GTTGGGAAGG GCGATCGGTG CGGGCCTCTT CGCTATTACG CCAGCTGGCG AAAGGGGGAT GTGCTGCAAG GCGATTAAGT TGGGTAACGC CAGGGTTTTC CCAGTCACGA CGTTGTAAAA CGACGGCCAG TGAATTGGAG GCTACAGTCA GTGGAGAGGA CTTTCACAGG CTGTCGCCGT GCTCATTTGA TAACTGCCCG TTATTCATGC GACACTTTCC TATATATGTC ACTCCAACTC CCACTAAAAT ATAAGATTTT TGAGAGTAAG CAAGCACTAG AACAGTAGGA AACACATTAT AGCTATTCAG TGAACTATTT CTTGAGTTAA TCAATCAATG GATGAGTGAA TCAATACAGT TCTTTGAGCG GGAAACTTTG TATAAGGCTC AGCTAAAAGG GAAATTGAGT GGGTCAGGTA CCACGGATAC TATACACTCT ATTGCATGAT TCTCCTGCCT ACATCAGAAG ACGTTTATAA GCCTATTTTA AAGGATACCA GTTGGAATCT CTCTTTTATT AATCACCAAG AGAACCATGA ACAAGCTGTT TATCATTTGA CTCATCATTT AATCTTGATT TCCAGCTTCT CACACTTGAA AGAAGACATA ATACATTTCT CACAGGATTC TGGGACTATT AACTGAACTT ATGTGTGTAA AAGGAATTCA TACAATGAAA GCACTAGAAA TAATTATTAT ACTTATAACC ATTGTATTTT TACATGTTTA AAATATAGCC ATAATTAGCC TACTCAAATC CAAGTGTAAA AGTAAAATGA TTTGCTTTCG TTTTGTTTTC CTTGCTTAGG GGATCCCTAG CATGGAGAGC GACGAGAGCG GCCTGCCCGC CATGGAGATC GAGTGCCGCA TCACCGGCAC CCTGAACGGC GTGGAGTTCG AGCTGGTGGG CGGCGGAGAG GGCACCCCCG AGCAGGGCCG CATGACCAAC AAGATGAAGA GCACCAAAGG CGCCCTGACC TTCAGCCCCT ACCTGCTGAG CCACGTGATG GGCTACGGCT TCTACCACTT CGGCACCTAC CCCAGCGGCT ACGAGAACCC CTTCCTGCAC GCCATCAACA ACGGCGGCTA CACCAACACC CGCATCGAGA AGTACGAGGA CGGCGGCGTG CTGCACGTGA GCTTCAGCTA CCGCTACGAG GCCGGCCGCG TGATCGGCGA CTTCAAGGTG ATGGGCACCG GCTTCCCCGA GGACAGCGTG ATCTTCACCG ACAAGATCAT CCGCAGCAAC GCCACCGTGG AGCACCTGCA CCCCATGGGC GATAACGATC TGGATGGCAG CTTCACCCGC ACCTTCAGCC TGCGCGACGG CGGCTACTAC AGCTCCGTGG TGGACAGCCA CATGCACTTC AAGAGCGCCA TCCACCCCAG CATCCTGCAG AACGGGGGCC CCATGTTCGC CTTCCGCCGC GTGGAGGAGG ATCACAGCAA CACCGAGCTG GGCATCGTGG AGTACCAGCA CGCCTTCAAG ACCCCGGATG CAGATGCCGG TGAAGAAAGA GTTTAAGAAT TCCGATCATA TTCAATAACC CTTAATATAA CTTCGTATAA TGTATGCTAT ACGAAGTTAT TAGGTCTGAA GAGGAGTTTA CGTCCAGCCA AGCTTAGGAT CTCGACCTCG AAATTCTACC GGGTAGGGGA GGCGCTTTTC CCAAGGCAGT CTGGAGCATG CGCTTTAGCA GCCCCGCTGG GCACTTGGCG CTACACAAGT GGCCTCTGGC CTCGCACACA TTCCACATCC ACCGGTAGGC GCCAACCGAC TCCGTTCTTT GGTGGCCCCT TCGCGCCACC TTCTACTCCT CCCCTAGTCA GGAAGTTCCC CCCCGCCCCG CAGCTCGCGT CGTGCAGGAC GTGACAAATG GAAGTAGCAC GTCTCACTAG TCTCGTGCAG ATGGACAGCA CCGCTGAGCA ATGGAAGCGG GTAGGCCTTT GGGGCAGCGG CCAATAGCAG CTTTGCTCCT TCGCTTTCTG GGCTCAGAGG CTGGGAAGGG GTGGGTCCGG GGGCGGGCTC AGGGGCGGGC TCAGGGGCGG GGCGGGCGCC CGAAGGTCCT CCGGAGGCCC GGCATTCTGC ACGCTTCAAA AGCGCACGTC TGCCGCGCTG TTCTCCTCTT CCTCATCTCC GGGCCTTTCG ACCTGCATCC ATCTAGATCT CGAGCAGCTG AAGCTTACCA TGACCGAGTA CAAGCCCACG GTGCGCCTCG CCACCCGCGA CGACGTCCCC AGGGCCGTAC GCACCCTCGC CGCCGCGTTC GCCGACTACC CCGCCACGCG CCACACCGTC GATCCGGACC GCCACATCGA GCGGGTCACC GAGCTGCAAG AACTCTTCCT CACGCGCGTC GGGCTCGACA TCGGCAAGGT GTGGGTCGCG GACGACGGCG CCGCGGTGGC GGTCTGGACC ACGCCGGAGA GCGTCGAAGC GGGGGCGGTG TTCGCCGAGA TCGGCCCGCG CATGGCCGAG TTGAGCGGTT CCCGGCTGGC CGCGCAGCAA CAGATGGAAG GCCTCCTGGC GCCGCACCGG CCCAAGGAGC CCGCGTGGTT CCTGGCCACC GTCGGCGTCT CGCCCGACCA CCAGGGCAAG GGTCTGGGCA GCGCCGTCGT GCTCCCCGGA GTGGAGGCGG CCGAGCGCGC CGGGGTGCCC GCCTTCCTGG AGACCTCCGC GCCCCACAAC CTCCCCTTCT ACGAGCGGCT CGGCTTCACC GTCACCGCCG ACGTCGAGGT GCCCGAAGGA CCGCGCACCT GGTGCATGAC CCGCAAGCCC GGTGCCTGAC GCCCGCCCCA CGACCCGCAG CGCCCGACCG AAAGGAGCGC ACGACCCCAT GCATCGATGA TATCAGATCC CCGGGATGCA GAAATTGATG ATCTATTAAA CAATAAAGAT GTCCACTAAA ATGGAAGTTT TTCCTGTCAT ACTTTGTTAA GAAGGGTGAG AACAGAGTAC CTACATTTTG AATGGAAGGA TTGGAGCTAC GGGGGTGGGG GTGGGGTGGG ATTAGATAAA TGCCTGCTCT TTACTGAAGG CTCTTTACTA TTGCTTTATG ATAATGTTTC ATAGTTGGAT ATCATAATTT AAACAAGCAA AACCAAATTA AGGGCCAGCT CATTCCTCCC ACTCATGATC TATAGATCTA TAGATCTCTC GTGGGATCAT TGTTTTTCTC TTGATTCCCA CTTTGTGGTT CTAAGTACTG TGGTTTCCAA ATGTGTCAGT TTCATAGCCT GAAGAACGAG ATCAGCAGCC TCTGTTCCAC ATACACTTCA TTCTCAGTAT TGTTTTGCCA AGTTCTAATT CCATCAGAAG CTGGTCGAGA TCCGGAACCC TTAATATAAC TTCGTATAAT GTATGCTATA CGAAGTTATT AGGTCCCTCG AAGAGGTTCA CTAGGCGCGC CACATTAACT GACATTCTTC AACACCAGAT CCGAGCTGTT CCCTTTGAGA ACCTTAACAT CCATTGTGGG GATGCCATGG ACTTAGGCTT AGAGGCCATT TTTGATCAAG TTGTGAGAAG AAATCGGGGT GGATGGTGTC TCCAGGTCAA TCATCTTCTG TACTGGGCTC TGACCACTAT TGGTTTTGAG ACCACGATGT TGGGAGGGTA TGTTTACAGC ACTCCAGCCA AAAAATACAG CACTGGCATG ATTCACCTTC TCCTGCAGGT GACCATTGAT GGCAGGAACT ACATTGTCGA TGCTGGGTTT GGACGCTCAT ACCAGATGTG GCAGCCTCTG GAGTTAATTT CTGGGAAGGA TCAGCCTCAG GTGCCTTGTG TCTTCCGTTT GACGGAAGAG AATGGATTCT GGTATCTAGA CCAAATCAGA AGGGAACAGT ACATTCCAAA TGAAGAATTT CTTCATTCTG ATCTCCTAGA AGACAGCAAA TACCGAAAAA TCTACTCCTT TACTCTTAAG CCTCGAACAA TTGAAGATTT TGAGTCTATG AATACATACC TGCAGACATC TCCATCATCT GTGTTTACTA GTAAATCATT TTCACTCTCG CCGGTTGGAC TTTAGATCAG AAGGGATCTT GCTGCCGCCC GAAAGAGGAA GGGCTGGAAG AGGAAGGAGC TTGGCGTAAT CATGGTCATA GCTGTTTCCT GTGTGAAATT GTTATCCGCT CACAATTCCA CACAACATAC GAGCCGGAAG CATAAAGTGT AAAGCCTGGG GTGCCTAATG AGTGAGCTAA CTCACATTAA TTGCGTTGCG CTCACTGCCC GCTTTCCAGT CGGGAAACCT GTCGTGCCAG CTGCATTAAT GAATCGGCCA ACGCGCGGGG AGAGGCGGTT TGCGTATTGG GCGCTCTTCC GCTTCCTCGC TCACTGACTC GCTGCGCTCG GTCGTTCGGC TGCGGCGAGC GGTATCAGCT CACTCAAAGG CGGTAATACG GTTATCCACA GAATCAGGGG ATAACGCAGG AAAGAACATG TGAGCAAAAG GCCAGCAAAA GGCCAGGAAC CGTAAAAAGG CCGCGTTGCT GGCGTTTTTC CATAGGCTCC GCCCCCCTGA CGAGCATCAC AAAAATCGAC GCTCAAGTCA GAGGTGGCGA AACCCGACAG GACTATAAAG ATACCAGGCG TTTCCCCCTG GAAGCTCCCT CGTGCGCTCT CCTGTTCCGA CCCTGCCGCT TACCGGATAC CTGTCCGCCT TTCTCCCTTC GGGAAGCGTG GCGCTTTCTC ATAGCTCACG CTGTAGGTAT CTCAGTTCGG TGTAGGTCGT TCGCTCCAAG CTGGGCTGTG TGCACGAACC CCCCGTTCAG CCCGACCGCT GCGCCTTATC CGGTAACTAT CGTCTTGAGT CCAACCCGGT AAGACACGAC TTATCGCCAC TGGCAGCAGC CACTGGTAAC AGGATTAGCA GAGCGAGGTA TGTAGGCGGT GCTACAGAGT TCTTGAAGTG GTGGCCTAAC TACGGCTACA CTAGAAGGAC AGTATTTGGT ATCTGCGCTC TGCTGAAGCC AGTTACCTTC GGAAAAAGAG TTGGTAGCTC TTGATCCGGC AAACAAACCA CCGCTGGTAG CGGTGGTTTT TTTGTTTGCA AGCAGCAGAT TACGCGCAGA AAAAAAGGAT CTCAAGAAGA TCCTTTGATC TTTTCTACGG GGTCTGACGC TCAGTGGAAC GAAAACTCAC GTTAAGGGAT TTTGGTCATG AGATTATCAA AAAGGATCTT CACCTAGATC CTTTTAAATT AAAAATGAAG TTTTAAATCA ATCTAAAGTA TATATGAGTA AACTTGGTCT GACAGTTACC AATGCTTAAT CAGTGAGGCA CCTATCTCAG CGATCTGTCT ATTTCGTTCA TCCATAGTTG CCTGACTCCC CGTCGTGTAG ATAACTACGA TACGGGAGGG CTTACCATCT GGCCCCAGTG CTGCAATGAT ACCGCGAGAC CCACGCTCAC CGGCTCCAGA TTTATCAGCA ATAAACCAGC CAGCCGGAAG GGCCGAGCGC AGAAGTGGTC CTGCAACTTT ATCCGCCTCC ATCCAGTCTA TTAATTGTTG CCGGGAAGCT AGAGTAAGTA GTTCGCCAGT TAATAGTTTG CGCAACGTTG TTGCCATTGC TACAGGCATC GTGGTGTCAC GCTCGTCGTT TGGTATGGCT TCATTCAGCT CCGGTTCCCA ACGATCGE100003, scramble sequence in pCas-Guide vector |
| OTI Disclaimer | These products are manufactured and supplied by OriGene under license from ERS. The kit is designed based on the best knowledge of CRISPR technology. The system has been functionally validated for knocking-in the cassette downstream the native promoter. The efficiency of the knock-out varies due to the nature of the biology and the complexity of the experimental process. |
| Reference Data | |
| RefSeq | NM_000662, NM_001160170, NM_001160171, NM_001160172, NM_001160173, NM_001160174, NM_001160175, NM_001160176, NM_001160179, NM_001291962 |
| UniProt ID | P18440 |
| Synonyms | AAC1; MNAT; NAT-1; NATI |
| Summary | This gene is one of two arylamine N-acetyltransferase (NAT) genes in the human genome, and is orthologous to the mouse and rat Nat2 genes. The enzyme encoded by this gene catalyzes the transfer of an acetyl group from acetyl-CoA to various arylamine and hydrazine substrates. This enzyme helps metabolize drugs and other xenobiotics, and functions in folate catabolism. Multiple transcript variants encoding different isoforms have been found for this gene. provided by RefSeq, Aug 2011 |
| Shipping | Ambient |
Reviews
Documents
| Product Manuals |
| FAQs |
| SDS |
Resources
Other Versions
| SKU | Description | Size | Price | |
|---|---|---|---|---|
| GA100003 | NAT1 CRISPRa kit - CRISPR gene activation of human N-acetyltransferase 1 | 1 kit |
$1,657.00
|
|
| KN221042BN | NAT1 - human gene knockout kit via CRISPR, HDR mediated | 1 kit |
$1,657.00
|
|
| KN221042LP | NAT1 - human gene knockout kit via CRISPR, HDR mediated | 1 kit |
$1,657.00
|
|
| KN221042RB | NAT1 - human gene knockout kit via CRISPR, HDR mediated | 1 kit |
$1,657.00
|
|
| KN421042 | NAT1 - KN2.0, Human gene knockout kit via CRISPR, non-homology mediated. | 1 kit |
$1,657.00
|
|
Citations
Arylamine N-acetyltransferase 1 deficiency inhibits drug-induced cell death in breast cancer cells: switch from cytochrome C-dependent apoptosis to necroptosis
McAleese, Butcher, Minchin
Breast Cancer Res Treat (2022) 195 (3), 223-236 DOI: 10.1007/s10549-022-06668-3
McAleese, Butcher, Minchin
Breast Cancer Res Treat (2022) 195 (3), 223-236 DOI: 10.1007/s10549-022-06668-3
Cited by 6
AI Summary: OriGene’s Human NAT1 gene knockout (KO) CRISPR/Cas9 kit (KN221042) was used to generate NAT1-deficient breast cancer cell lines, enabling the study of how NAT1 loss affects drug-induced cell death mechanisms.
Snippet: icillin/streptomycin (Thermo Fisher Scientific) at 37 °C with 5% CO2. CRISPR/Cas9 knockout of NAT1 Disruption of the NAT1 gene was achieved through a human NAT1 gene knockout (KO) CRISPR/Cas9 kit (OriGene Technologies, KN221042). This kit contained two gRNA vectors, a donor vector with the green fluorescent protein gene and puromycin selection cassette and a scramble gRNA vector to act as a co
Loss of human arylamine N-acetyltransferase I regulates mitochondrial function by inhibition of the pyruvate dehydrogenase complex
Wang, Minchin, Essebier et al
Int. J. Biochem. Cell Biol. (2019) 110, 84-90 DOI: 10.1016/j.biocel.2019.03.002
Wang, Minchin, Essebier et al
Int. J. Biochem. Cell Biol. (2019) 110, 84-90 DOI: 10.1016/j.biocel.2019.03.002
AI Summary: OriGene’s Human NAT1 Gene Knockout CRISPR/Cas9 Kit (KN221042) was used to generate the NAT1 knockout MDA-MB-231 cell line, enabling the study of NAT1’s role in mitochondrial function in this paper.
Snippet: … The MDA-MB-231 NAT1 knockout cell line was generated by disrupting the NAT1 gene using a human NAT1 gene knockout CRISPR/Cas9 kit (Origene Technologies, Rockville, MD;KN221042). NAT1 knockout;;NAT1 knockout cell line has been described previously (Wang et al., 2018). The MDA-MB-231 NAT1 knockout cell line was generated by disrupting the NAT1 gene using a human NAT1 gene knockout CRISPR/Cas9 kit (Origene Technologies, Rockville, MD;KN221042). NAT1 knockout was verified by PCR of genomic DNA, lack of NAT1 acetylation activity and Western blot for NAT1 protein, as previously described (Wang et al., 2018)
Arylamine N-acetyltransferase 1 protects against reactive oxygen species during glucose starvation: Role in the regulation of p53 stability
Wang, Minchin, Butcher
PLoS ONE (2018) 13 (3), e0193560 DOI: 10.1371/journal.pone.0193560
Wang, Minchin, Butcher
PLoS ONE (2018) 13 (3), e0193560 DOI: 10.1371/journal.pone.0193560
AI Summary: In this study, OriGene's siRNA was used to inhibit p53 expression in HT-29 cells, enabling the researchers to investigate the role of p53 in reactive oxygen species production and apoptosis following NAT1 knockout.
Snippet: For siRNA transfections, 20 nM siRNA (Origene) was used with Lipofectamine RNAiMAX reagent (Invitrogen) according to the manufacturer's instructions. A scrambled sequence was used as a control. CRISPR/Cas9 knockout of NAT1 Cached
Showing 1-3 of 3 papers.
Powered by BizGenius
*Delivery time may vary from web posted schedule. Occasional delays may occur due to unforeseen
complexities in the preparation of your product. International customers may expect an additional 1-2 weeks
in shipping.
Related Products
- Price:
- Actual Price:
Welcome to OriGene AI!
I'm your AI-powered guide to everything OriGene.
Ask me anything:
- Product specs
- Ordering help
- Technical questions
- How to find exactly what your experiment needs
Prefer a live agent? Connect with us by clicking the green chat icon, as seen in the image below or email our team at custsupport@origene.com.
